Chronic kidney disease (CKD) affects over 850 million people globally, and there is an
urgent need to prevent its development and progression. During the last decade, new …

The burden of chronic kidney disease (CKD) and its risk factors are projected to rise in
parallel with the rapidly ageing global population. By 2050, the prevalence of CKD category …

Background and objectives: Polypharmacy and chronic kidney disease (CKD) are becoming
increasingly common due to an ageing population and the rise of multimorbidity. In line with …

People living with chronic kidney disease (CKD) frequently suffer from mild cognitive
impairment and/or other neurocognitive disorders. This review in two parts will focus on …

Results The mean±SD eGFR at baseline was 44±15 ml/min per 1.73 m 2, and participants
had a median of six (interquartile range 3–11) simultaneous assessments of eGFR and …

Introduction Polypharmacy might contribute to a range of adverse outcomes, which could get
worse in the elderly with chronic kidney disease (CKD). Evidence on polypharmacy, CKD …

Rationale & Objective Adverse drug reactions (ADRs) are common in patients with chronic
kidney disease (CKD). The impact of kidney function decline on serious ADR risk has been …

Older hospitalized patients with chronic kidney disease (CKD) are part of the geriatric
population with a substantial risk of potentially inappropriate medication (PIM) use. The high …

Results At exit, the eKidneyCare group had fewer total medication discrepancies compared
with MyMedRec (median, 0.45; interquartile range, 0.33–0.63 versus 0.67; interquartile …

Objective To evaluate the efficacy, safety, and tolerability of inclisiran in participants with
atherosclerotic cardiovascular disease (ASCVD) from ORION-10 and ORION-11 stratified by …